Greenwich LifeSciences (NASDAQ:GLSI) Given “Buy” Rating at HC Wainwright

Greenwich LifeSciences (NASDAQ:GLSI)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $38.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 210.33% from the company’s current price.

Greenwich LifeSciences Price Performance

Shares of Greenwich LifeSciences stock traded up $0.02 on Tuesday, hitting $12.25. 8,664 shares of the company’s stock traded hands, compared to its average volume of 36,183. The firm’s 50-day moving average price is $12.73 and its two-hundred day moving average price is $13.57. The stock has a market capitalization of $161.02 million, a PE ratio of -15.31 and a beta of 1.69. Greenwich LifeSciences has a one year low of $8.15 and a one year high of $21.44.

Insider Buying and Selling at Greenwich LifeSciences

In other news, CEO Snehal Patel purchased 3,200 shares of the firm’s stock in a transaction dated Monday, December 30th. The stock was bought at an average price of $11.12 per share, with a total value of $35,584.00. Following the acquisition, the chief executive officer now directly owns 5,539,302 shares of the company’s stock, valued at approximately $61,597,038.24. This represents a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders acquired 10,500 shares of company stock worth $128,459. Insiders own 51.67% of the company’s stock.

Hedge Funds Weigh In On Greenwich LifeSciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC grew its holdings in shares of Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after buying an additional 6,538 shares during the period. Garden State Investment Advisory Services LLC acquired a new position in Greenwich LifeSciences in the 3rd quarter worth $253,000. State Street Corp raised its stake in shares of Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after purchasing an additional 3,005 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after purchasing an additional 5,861 shares in the last quarter. Institutional investors and hedge funds own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.